Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
  • COVID-19 Long-Haulers
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Wednesday, April 7

Antibody-based strategies in HIV therapy

Leronlimab in International Journal of Infectious Diseases

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

Local drug trial provides hope for COVID ‘long-haulers’

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Leronlimab and Long-Haulers

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Case Study of Critically Ill Person with COVID-19 on ECMO Successfully Treated with Leronlimab Published in Journal of Translational Autoimmunity

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn Inc. Announces First HIV Patient Dosing With PRO 140 in Phase 2b Clinical Trial for Treatment Substitution Protocol

May 14, 2014 8:00am EDT

CytoDyn Announces Investor Call to Provide Update on Clinical Development Strategy

Mar 19, 2014 8:05am EDT

CytoDyn Submits Protocol to FDA for Phase 2b Clinical Study of PRO 140 for Treatment Substitution in Patients with HIV

Feb 18, 2014 8:05am EST

CytoDyn Appoints Denis R. Burger, Ph.D. to Board of Directors

Feb 13, 2014 8:05am EST

CytoDyn to Present at 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 10:00 AM Eastern

Feb 05, 2014 7:35am EST

CytoDyn Signs Agreement with Amarex Clinical Research LLC to Prepare Two Phase 2b Clinical Trial Protocols to Explore Two Additional Therapeutic Indications for PRO 140

Jan 28, 2014 8:05am EST

CytoDyn to Webcast Presentation at Biotech Showcase 2014 in San Francisco on Monday, January 13, at 2:30 PM Pacific

Jan 08, 2014 8:05am EST

CytoDyn Submits Phase IIb Protocol for PRO 140 Clinical Trial to FDA

Oct 30, 2013 3:59pm EDT

CytoDyn Inc. Appoints David Feigal, M.D., as Chief Medical Officer

Oct 25, 2013 9:00am EDT

CytoDyn Inc. Completes $14.5 Million Private Equity Offering

Oct 24, 2013 7:40pm EDT
RSS
  • Prev
    • 1...
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    • 34
    • 35
    Next
    © 2021 CytoDyn Inc. All Rights Reserved.
    • Twitter
    • Facebookj
    Privacy Policy Disclaimer Sitemap